Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Polidocanol Endovenous Microfoam (PEM)
Polidocanol Endovenous Microfoam · 1 trial · 1 indication
Cmax measured and adjusted for weight
| Arm | Type | Description |
|---|---|---|
| High Dose Polidocanol Endovenous Microfoam | EXPERIMENTAL | - |
| Medium Dose Polidocanol Endovenous Microfoam | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Polidocanol Endovenous Microfoam (PEM) | DRUG | Pharmacokinetic comparison of different doses of drug |
Inclusion Criteria: * Male or female; age 18 to 75 years * Superficial venous disease where SFJ incompetence is the predominant source of reflux (reflux \> 0.5 seconds on duplex ultrasonography) associated with incompetence of the great saphenous vein (GSV) or other major accessory vein * Expected ...
Polidocanol Endovenous Microfoam is being studied for the treatment of varicose veins, a cardiovascular condition. It is an investigational small molecule therapy that has been evaluated in a Phase 1 clinical trial. It is not described as approved for any use.
Polidocanol Endovenous Microfoam is being developed by Boston Scientific Corporation, which trades under the ticker BSX. The company is the sponsor behind the clinical development program for this varicose vein treatment candidate.
Polidocanol Endovenous Microfoam is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. It is an investigational agent and has not been established as an approved therapy for varicose veins.
Polidocanol Endovenous Microfoam has been studied in one completed Phase 1 trial, NCT01428076, titled a pharmacokinetic study of Polidocanol Endovenous Microfoam. That randomized, controlled trial enrolled 21 participants with varicose veins in the United States and included adults aged 18 years and older.
Yes, Polidocanol Endovenous Microfoam is also known as PEM. PEM is simply the abbreviated form of the full drug name used in trial titles and references, so searches for either term refer to the same investigational varicose vein therapy developed by Boston Scientific Corporation.